Business
Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report
LYON, France, April 30, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic diseases, including certain rare diseases (the "Company"), announces the postponement of the publication of its annual financial statements for the fiscal year ended December 31, 2025, and its 2025 annual financial report.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/fc77c0ae6968d6db2c84dc7a473f9e91"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zQHSIbLXHdjm7QAGHb4hjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMg--/https://media.zenfs.com/en/business-wire.com/fc77c0ae6968d6db2c84dc7a473f9e91","width":480,"height":256}},"lazy":false},{"type":"text","content":"LYON, France, April 30, 2026--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic diseases, including certain rare diseases (the "Company"), announces the postponement of the publication of its annual financial statements for the fiscal year ended December 31, 2025, and its 2025 annual financial report.","length":379,"tagName":"p"},{"type":"text","content":"This decision is related to the completion, since the Lyon Commercial Court approved the continuation plan on January 22, 2026, of several significant transactions whose accounting treatment requires additional time to finalize the annual report, namely:","length":254,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"the establishment of an equity financing facility with IRIS, announced on February 3, 2026, for a maximum amount of €5 million over 5 years, through the issuance of stock warrants;","length":180,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"the signing of the Tranche D PDR subscription agreement with IPF Invest Co 2 S.à.r.l. and IPF Management SA, announced on March 25, 2026, for an aggregate nominal amount of €3.75 million, which was automatically increased to €7.5 million following the completion of the sale of the PXL770 assets to Scynexis;","length":308,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"the conclusion of the agreement to sell PXL770 to Scynexis, announced on March 31, 2026, under which the amounts paid by Scynexis pursuant to the PXL770 sale agreement will be received by the Company1.","length":201,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":689,"olType":false},{"type":"text","cont...